A 337

Drug Profile

A 337

Alternative Names: A337

Latest Information Update: 16 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Generon (Shanghai) Corporation
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action CD3 antigen stimulants; Epithelial cell adhesion molecule modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 16 Aug 2017 Generon (Shanghai) Corporation plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease) in Australia (ACTRN12617001181392)
  • 14 Jun 2017 Phase-I clinical trials in Solid tumours (Late-stage disease) in Australia (unspecified route)
  • 23 Aug 2016 Preclinical trials in Solid tumours in China (unspecified route) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top